On June 28, 2021 Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reported that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021 (Press release, Biocept, JUN 28, 2021, View Source [SID1234584421]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased that Biocept will now be included in the Russell Microcap Index, which is a broadly used performance benchmark for smaller growth stocks in the U.S.," said Michael Nall, President and CEO of Biocept. "This is an exceptionally exciting time with the full commercial launch underway of our novel, proprietary CNSide assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors that have metastasized to the central nervous system. We believe the addition to the Russell Microcap Index will further raise awareness of Biocept within the global investment community."
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s U.S. indexes. For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.